Contribution ID: 0b698515-e790-4223-bb08-576d07831184
Date: 18/02/2019 08:04:22

Questionnaire to MS to report on their experience with Directive 2009/41/EC - Update for 2018

Fields marked with * are mandatory.

Introduction

Directive 2009/41/EC on the contained use of genetically modified micro-organisms ("GMMs")* (hereinafter referred to as "the Directive") provides that every three years Member States must send to the Commission a summary report on their experience with the Directive (Article 17(2)) and that the Commission must publish a summary based on these reports (Article 17(3)).
In accordance with such articles, the Commission has already published four reports for the periods 1999-2003, 2003-2006, 2006-2009 and 2009-2014 (reports are available on this European Commission webpage).

Last year, the Commission invited Competent Authorities of Member States under the Directive to complete a questionnaire covering the period ranging from 6 June 2014 to 31 December 2017.
We are now asking you to complete an updated version of the questionnaire for the period **1 January 2018 – 31 December 2018**, to also cover the impact of the outcome of the ruling of the Court of Justice of the European Union on new mutagenesis techniques (Case C-528/16) in the Commission report, which will therefore cover the period June 2014 - December 2018.

QUESTIONNAIRE
The questionnaire is divided into five parts, to collect information **for the year 2018**:

- Part I focuses on possible updates on your experience with the general implementation of the Directive.
- Part II aims at getting an overview of contained uses and premises for GMMs. It also contains additional questions on GM animals/GM plants if they are covered under your contained use legislation**.
- Part III focuses on investigational medicinal products that contain or consist of GMOs.
- Part IV concerns gene drive modified organisms.
- Part V allows for additional comments.

A glossary list with definitions of terms used in the questionnaire has been included in **Annex**.

DEADLINE FOR COMPLETION: 29 March 2019

* For the definition of "contained use", "micro-organism" and "GMM" see the Annex.
** For the notion of "contained use legislation" see the Annex.

Annex - Glossary of terms (for the purposes of this questionnaire)

Download this document to check the definitions of terms or the purposes of this questionnaire

Annex.pdf

Contact details

*Member State

Lithuania

*Competent Authority

Ministry of Environment

*Contact person *(this information will not be publicly disclosed)*

Odeta Pivoriene

*Email

odeta.pivoriene@am.lt

Telephone

+37052786530

PART I: GENERAL IMPLEMENTATION OF THE DIRECTIVE

***1. Notification and approval systems (and relevant changes)**

Was there a change **in 2018** regarding the Competent Authority (CA) for Directive 2009/41/EC on the contained use of GMMs?

- Yes
- No

***In 2018**, has the scope of the transposing legislation been changed in your Member State?

- Yes
- No

***In 2018**, did you have any change in the notification and approval system in your Member State?

- Yes
- No

* **In 2018**, in your Member State, what was the percentage of notifications* which were not processed within the statutory timeframe?

* *For the definition of "notification" see the Annex.*

- 0%

- ○ > 0%

* From your experience **in 2018**, do you have new information to report about difficulties in relation to the notification process (including causes for delays in the notification process, actions taken to reduce those delays)?
  - ○ Yes
  - ◉ No

* **2. Waste disposal**

Do you have changes to report regarding waste disposal for 2018, compared to the information already reported for the period 2014 - 2017?
  - ○ Yes
  - ◉ No

* Is waste from contained use activities recycled after inactivation?
  - ◉ Yes
  - ○ No

* Specify for which purpose(s)

It depends on recycled content

* **3. Inspection and enforcement issues**

In 2018, did you implement changes in the procedure undertaken for the inspection of contained use premises (Article 16 of the Directive) under your contained use legislation?
  - ○ Yes
  - ◉ No

* **In 2018,** how many premises/contained uses have been inspected?

4

* **In 2018**, what were the issues most frequently encountered during the course of inspections carried out?

-

* What were the corresponding enforcement actions taken?

-

* What actions were taken by the user (and/or advised by the CA) in order to minimise the occurrence of these issues in the future?

-

What type of corrective and/or preventive actions, if any, did you apply in order to minimise the occurrence of these issues in the future?

	Issue	Enforcement action(s)	Corrective/preventive measure(s)
1			
2			
3			
4			
5			

***4. Accidents**

Provide information reported by the users on accidents* (as required in Article 14(1) of the Directive) to the CA **for 2018**.

* *For the definition of "accident" see the Annex.*

0

*Provide information on the measures taken by you, as a CA, on the basis of Articles 14(2) and 15(1) of the Directive.

0

Comment on a possible improvement regarding the occurrence of similar accidents, as a result of the measures taken by the user(s) and/or by the CA.

***5. Public consultation**

Do you have new information to report regarding public consultation under your contained use legislation (in accordance with Article 12 of the Directive), compared to the information already reported for the period 2014 - 2017?

- Yes
- No

6. Interpretation and implementation of Directive 2009/41/EC

*Please provide information regarding notifications of contained uses of GMMs (and GMOs when appropriate) produced with new mutagenesis techniques:

The Competent Authority of Directive 2009/41 has not received any application linked to new mutagenesis techniques yet.

*Please provide information and views on the impact of the outcome of the ruling of the Court of Justice of the European Union on new mutagenesis techniques for you as CA for Directive 2009/41/EC. Provide also information on how such impact is or will be addressed in your country:

There is no experience how to handle such type of Applications and what criteria to use for risk assessment and how to assess the risk itself. It would be helpful better explanation of the list of New mutagenesis techniques and what risk assessment methodology and safety measures to use for each New mutagenesis technique. Harmonized EU legislation of New mutagenesis techniques would be welcome.

PART II: OVERVIEW OF CONTAINED USES AND PREMISES

In this part of the questionnaire you are invited to submit information on the number of notifications and amendments submitted for contained uses of GMMs and on the number of premises for contained use of GMMs, according to the classification of contained use. If also covered under your contained use legislation, similar questions for GMOs (GM animals and GM plants) will be asked.

7. GMMs

How many **notifications of contained uses of GMMs** were submitted in your Member State under the Directive **in 2018**?

Report all types of notifications and amendments to existing notifications by class; this includes GMMs, combined uses of GMMs and GMOs (to be reported according to the GMM class), clinical trials (where applicable) and gene drive modified organisms (where applicable).

* Classification of contained use (according to Art. 4(3))

	No. of notifications submitted (according to Art. 6, 8 and 9)	**No. of amendments** (according to Art. 11)
* Class 1*	1	0
* Class 2*	0	0
* Class 3*	0	0
* Class 4*	0	0
***Total**	1	0

Number of **premises for contained uses of GMMs** (as referred to in Article 6) with a valid notification* as per December 2018:

* *For a definition of "valid notification" see the Annex.*

	No. of premises	Comments (if any)
* Class 1	14	0
* Class 2	1	0
* Class 3	0	0
* Class 4	0	0
* **Total**	15	To date number of labs according to Valid notification

Number of **contained uses of GMMs** (including combined uses of GMMs and GMOs) with a valid notification* or approval as per December 2018:

* *For a definition of "valid notification" see the Annex.*

	No. of contained uses	Comments (if any)
* Class 2	2	0
* Class 3	0	0
* Class 4	0	0
* **Total**	2	To date number of activities according to valid notifications

8. GM animals and GM plants

If also covered under your contained use legislation, how many **notifications** for contained uses of GMOs, i.e. GM animals and GM plants, (excluding combined uses with GMMs) were submitted in your Member State **in 2018**?

* *If you use a different classification system (than classes 1, 2, 3, 4), explain the link between the classification and the category of the risk.*

	Classification of contained use*	**GM animals** - No of **notifications submitted**	**GM animals** - No of amendments	**GM plants** - No of **notifications submitted**	**GM plants** - No of amendments
*a	0	1	0	0	0
*b	0	0	0	0	0
*c	0	0	0	0	0
*d	0	0	0	0	0
***Total**	0	1	0	0	0

* Did you encountered specific challenges related to **notifications** about GM plants or GM animals?

The activity is with already genetically modified mice, 1st risk class

PART III: INVESTIGATIONAL MEDICINAL PRODUCTS THAT CONTAIN OR CONSIST OF GMOs

In this part of the questionnaire you are invited to submit information about the different activities related to the manufacturing and administration of investigational medicinal products for human and veterinary use that contain or consist of GMOs.*

If manufacturing of investigational medicinal products is common for both human and veterinary use, please report this activity under the "Human use" part.

* *This includes but is not limited to Advanced Therapy Medicinal Products ("ATMPs"). For a definition of ATMP see the Annex.*

*** 9. Human use - Manufacturing**

Is the manufacturing of investigational medicinal products for human use that contain or consist of GMOs notified and/or authorised under Directive 2009/41/EC in your Member State?

- ○ Yes
- ◉ No

* What challenges, if any, did you as a CA encounter in implementing the Directive in relation to the manufacturing of investigational medicinal products for human use that contain or consist of GMOs (e.g. notification, risk assessment, authorisation, control, etc.)?

-

* What in your opinion should be done or is done already to address these challenges?

-

*** 10. Human use - Administration (clinical trials)**

Is the administration of investigational medicinal products for human use that contain or consist of GMOs notified and/or authorised under Directive 2009/41/EC in your Member State?

- ○ Yes
- ◉ No

* What challenges, if any, did you as a CA encounter in implementing the Directive in relation to the administration of investigational medicinal products for human use that contain or consist of GMOs (e. g. notification, risk assessment, authorisation, control, etc.)?

-

* What in your opinion should be done or is done already to address these challenges?

-

*11. Veterinary use - Manufacturing

Is the manufacturing of investigational medicinal products for veterinary use that contain or consist of GMOs notified and/or authorised under Directive 2009/41/EC in your Member State?

- Yes
- No

*What challenges, if any, did you as a CA encounter in implementing the Directive in relation to the manufacturing of investigational medicinal products for veterinary use that contain or consist of GMOs (e.g. notification, risk assessment, authorisation, control, etc.)?

-

*What in your opinion should be done or is done already to address these challenges?

-

*12. Veterinary use - Administration (clinical trials)

Is the administration of investigational medicinal products for veterinary use that contain or consist of GMOs notified and/or authorised under Directive 2009/41/EC in your Member State?

- Yes
- No

*What challenges, if any, did you as a CA encounter in implementing the Directive in relation to the administration of investigational medicinal products for veterinary use that contain or consist of GMOs (e.g. notification, risk assessment, authorisation, control, etc.)?

-

*What in your opinion should be done or is done already to address these challenges?

-

PART IV: GENE DRIVE MODIFIED ORGANISMS

The purpose of this section is to gather information on whether notifications for contained uses of gene drive* modified organisms have been submitted in the Member States and how the Directive is implemented in this respect.

* *For the purpose of this questionnaire, the definition of "gene drive" given in the Annex is applicable.*

*In 2018, has your Member State taken any measure regarding gene drive modified organisms under the Directive?

- Yes
- No

* **In 2018**, have you received notifications on gene drive modified organisms under your contained use legislation?

- ○ Yes
- ◉ No

* Are you implementing specific containment measures for gene drive modified organisms?

- ○ Yes
- ◉ No

* Are there any particular challenges, for you as a CA, in implementing the Directive with regard to the contained use of gene drive modified organisms (e.g. notification, risk assessment, authorisation, control, etc.)?

- ◉ Yes
- ○ No

Provide details:

There is no experience how to handle such type of Applications and what criteria to use for risk assessment and how to assess the risk itself.

* What in your opinion should be done or is done already to address the challenges identified, with the aim to facilitate the implementation of the Directive?

It would be helpful clearer explanation of GM gene drive and what risk assessment methodology and safety measures to use. Harmonized EU legislation for Gene drive would be welcome.

PART V: ADDITIONAL COMMENTS

Thanks for providing comments on any other aspects of the Directive or on other related legislation.

Contact

Beatrice.MARQUEZ-GARRIDO@ec.europa.eu